Firstly, the sample size of the published datasets is small, which means that our findings need to be validated in larger datasets and clinical trials to determine whether AOX1, APOC1, armcx1, FLRT3, gstm2, and HPN can be used as biomarkers of PCa. This evidence concerns the gene HPN and posterior cortical atrophy.